Order Article Reprints

Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, et al. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021; 13(8):1642. https://doi.org/10.3390/v13081642

Peiffer-Smadja, Nathan, Antoine Bridier-Nahmias, Valentine Marie Ferré, Charlotte Charpentier, Mathilde Garé, Christophe Rioux, Aude Allemand, Philippa Lavallée, Jade Ghosn, Laura Kramer, and et al. 2021. "Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2" Viruses 13, no. 8: 1642. https://doi.org/10.3390/v13081642

Peiffer-Smadja, N., Bridier-Nahmias, A., Ferré, V. M., Charpentier, C., Garé, M., Rioux, C., Allemand, A., Lavallée, P., Ghosn, J., Kramer, L., Descamps, D., Yazdanpanah, Y., & Visseaux, B. (2021). Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses, 13(8), 1642. https://doi.org/10.3390/v13081642